The study, published in the journal Pharmacia, describes a three-part composite platform. Clobetasol propionate was first encapsulated in nanoliposomes, vesicles built from soybean phosphatidylcholine and cholesterol with phospholipid bilayers capable of carrying both water-loving and fat-loving drugs. These nanovesicles were then dispersed in a Carbopol 940 hydrogel enriched with hyaluronic acid and glycerin, creating a moist, adhesive matrix that clings to the skin and prolongs residence time. Finally, microneedle-like trichomes harvested from Urtica dioica, the stinging nettle, were washed repeatedly and folded into the gel, giving the formulation a physical penetration-enhancing arm that no synthetic patch can match for simplicity.

The nettle’s contribution is elegant in its biology. Anatomical measurements of its stinging hairs, technically called trichomes, show an average length of 1.38 millimeters with a hollow lumen of roughly 3.85 nanoliters, an elongated, acicular architecture that behaves like a naturally occurring microneedle. When the delicate tip contacts skin, it fractures, allowing the sharp shaft to pierce the stratum corneum and release its contents. In the engineered formulation, that piercing action is purely mechanical, creating microchannels through which the nanoliposomal payload can diffuse into deeper epidermal layers. The hollow interior, once emptied of its natural cargo, may also serve as an additional micro-reservoir for drug entrapment.

Before the trichomes could be safely deployed, the team had to solve a serious safety problem. Nettle stinging hairs contain histamine, serotonin, acetylcholine, and formic acid, the very molecules responsible for the plant’s notorious sting. Because these compounds are water-soluble, the researchers subjected the isolated trichomes to up to ten successive washing cycles with deionized water, monitoring the process by high-performance liquid chromatography. Chromatograms after the first cycle showed prominent peaks corresponding to the irritants, but these diminished steadily with each wash until, after the tenth cycle, the chromatogram was indistinguishable from that of pure water, confirming removal of the stinging chemistry while the needle-like morphology remained intact.

The nanoliposomal component was optimized through a systematic screen of 24 formulations, varying drug-to-lipid ratio, phosphatidylcholine-to-cholesterol ratio, hydration pH, sonication time, and hydration temperature. The winning formula, designated F2, achieved a vesicle size of approximately 100 nanometers, a low polydispersity index of 0.152 indicating a narrow and uniform size distribution, and a moderate zeta potential of −16.73 millivolts. Encapsulation efficiency reached 98.8 percent by the indirect method and 94.3 percent by the direct method, remarkable figures for a lipophilic corticosteroid. Vesicles below 200 nanometers are known to penetrate skin more effectively, making this size range well suited to transport across the thickened psoriatic barrier once microneedle-assisted channels are available.

Physicochemical characterization of the freeze-dried optimum formulation confirmed successful drug incorporation. Fourier-transform infrared spectroscopy showed disappearance of the characteristic clobetasol propionate peaks in the lyophilized nanoliposomes, consistent with encapsulation rather than simple physical blending. Thermogravimetric analysis revealed dramatically enhanced thermal stability, with only 8.068 percent weight loss at approximately 350 degrees Celsius compared with 50.29 percent degradation of the pure drug at around 220 degrees, an effect attributed to the protective lipid bilayer. Differential scanning calorimetry and X-ray diffraction indicated conversion of the crystalline drug into a partially amorphous or molecularly dispersed state within the lipid matrix, while field-emission scanning electron microscopy captured spherical nanosized vesicles with smooth surfaces and uniform distribution preserved after freeze-drying.

The hydrogel arm of the platform was tuned by testing two Carbopol 940 concentrations, 0.5 and 2 percent by weight. The more viscous 2 percent gel, F2Hb, showed slower in vitro drug release, delivering 65.69 percent of its payload over eight hours, compared with 74.47 percent from the 0.5 percent gel and 92.33 percent from the marketed Promax product. This sustained profile reflects the dual diffusion barrier created by the tightly cross-linked polymer network and the lipid bilayer encapsulating the corticosteroid. Release kinetics fit the zero-order model with a Korsmeyer–Peppas exponent above 0.45, indicating non-Fickian diffusion governed by both molecular diffusion and polymer swelling, a combination that favors prolonged, controlled delivery rather than an immediate burst.

Ex vivo permeation across excised rat skin revealed a nuanced picture. The nanoliposomal hydrogel with nettle trichomes, F2HbM, achieved a steady-state flux of 48.87 micrograms per square centimeter per hour with a short lag time of 0.39 hours, and produced the highest cumulative skin deposition of 140.127 micrograms per square centimeter after 24 hours, compared with only 9.984 micrograms per square centimeter for the commercial product. Notably, the trichomes’ mechanical action depends on frictional application, and the small 1.5-square-centimeter diffusion area of the ex vivo setup limited their full function, which the authors acknowledge may cause such models to underestimate mechanically assisted delivery systems.

The decisive evidence came from an imiquimod-induced mouse model of psoriasis, in which daily application of the cream triggers psoriasiform lesions marked by erythema, scaling, and skin thickening. Mice treated with F2HbM showed the greatest reduction in these symptoms and the sharpest decline in the key inflammatory cytokines interleukin-17A and interleukin-23, dropping to 101.97 and 103.04 respectively, far below the levels observed in mice treated with the commercial product, which reached 229.372 and 242.147. The nanoliposomal hydrogel without trichomes performed less well, and a hydrogel containing free drug plus trichomes but no nanoliposomes fell short of the full composite, pointing to a genuine synergy between sustained lipid-encapsulated release and microneedle-facilitated penetration.

Safety testing over 72 hours showed the composite formulation was well tolerated, with erythema and edema scores approaching zero, likely reflecting the controlled release profile that minimizes immediate free-drug exposure and the thorough washing that removed the nettle’s irritant chemistry. The authors caution that long-term storage stability and clinical translation remain to be confirmed, but the study demonstrates a compelling proof of concept: a single topical system that pairs a potent corticosteroid with biocompatible nanovesicles, an adhesive hydrogel, and plant-derived microneedles, engineered to overcome one of dermatology’s most resistant biological barriers while favoring local drug retention over systemic exposure.

}

Subject of Research: A clobetasol propionate-loaded nanoliposomal Carbopol hydrogel combined with washed stinging nettle trichomes improved skin deposition and reduced psoriasis-like inflammation in mice.

Article Title: Development and evaluation of clobetasol propionate-loaded nanoliposomal hydrogel integrated with plant-derived microneedle-like microstructures for site-specific psoriasis therapy

Article References: Jafer, S. S., & Almajidi, Y. Q. (2026). Development and evaluation of clobetasol propionate-loaded nanoliposomal hydrogel integrated with plant-derived microneedle-like microstructures for site-specific psoriasis therapy. Pharmacia, 73, Article e199561. https://doi.org/10.3897/pharmacia.73.e199561

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e199561

Keywords: psoriasis, nanoliposomes, clobetasol propionate, stinging nettle, microneedles, drug delivery, hydrogel, topical therapy, skin barrier, cytokines, Development, evaluation

The trial, conducted at RDC Clinical in Brisbane, Australia, between July and December 2025, was prospectively registered with ClinicalTrials.gov and approved by an independent ethics committee. Participants were randomly allocated in a one-to-one ratio to receive either the active softgel capsules or an identical placebo containing only sunflower oil. The active capsules delivered 28 to 30 milligrams of mixed carotenoids daily, a blend of lutein, zeaxanthin, alpha-carotene, beta-carotene, and lycopene, the same pigments that give carrots, tomatoes, and leafy greens their vivid colors. Investigators, participants, and even the statistician analyzing the data remained blinded to group assignments throughout, and compliance was impressively high, averaging near or above the full prescribed dose in both arms.

The scientific rationale for the study rests on decades of work showing that carotenoids are among the skin’s most important dietary allies. Skin aging unfolds through two overlapping pathways: intrinsic aging, driven by genetics, metabolism, and hormonal shifts, and extrinsic aging, driven by ultraviolet radiation, smoking, and pollution. Both converge on the production of reactive oxygen species, unstable molecules that damage proteins, lipids, and DNA, degrading the collagen and elastic fibers that keep skin firm and resilient. Carotenoids counter this assault in two ways, directly neutralizing free radicals and switching on the body’s own antioxidant enzymes, including superoxide dismutase, catalase, and glutathione peroxidase. When ingested, they accumulate in the skin, where they also absorb specific wavelengths of ultraviolet light and dissipate the energy as harmless heat, providing a form of internal photoprotection.

The timing of the intervention was no accident. Women in their forties and fifties face a particularly punishing hormonal transition for their skin. Estrogen normally stimulates fibroblasts to produce collagen and promotes hyaluronic acid synthesis, which locks moisture into the tissue and limits water escaping through the surface. As estrogen declines through perimenopause and menopause, collagen production falters while its breakdown accelerates; skin collagen is estimated to fall by roughly thirty percent during the first five years of menopause, and a further two percent each year afterward. The result is thinning, dryness, and a weakening of the skin barrier, precisely the deficits the Brisbane team set out to measure with objective instruments rather than subjective impressions.

Those instruments were put to work at baseline, week six, and week twelve. A high-resolution imaging system, the A-One Smart Pro, photographed each participant’s face under normal, ultraviolet, and polarized lighting, using algorithms to score wrinkles, elasticity, moisture, sebum, pigmentation, pore size, and temperature. A separate DermaLab Combo system measured transepidermal water loss, or TEWL, the gold-standard indicator of skin barrier function, and used high-frequency ultrasound to gauge dermal thickness. Meanwhile, a non-invasive spectroscopy device called the Veggie Meter quantified the carotenoids actually present in each participant’s skin, providing a direct readout of whether the supplement was reaching its target tissue.

The headline result was a striking negative. At both week six and week twelve, there were no significant differences between the active and placebo groups on any of the visible aging parameters, meaning the supplement did not visibly smooth wrinkles, tighten pores, or brighten pigmentation over the study period. One unexpected wrinkle in the data even favored placebo: the control group showed a larger improvement in elasticity scores over time. The researchers acknowledge that the trial may have been underpowered for visible outcomes, since their sample size calculation was based on effect estimates drawn from a physiologically different study of eye health, an acknowledged limitation that introduces uncertainty into the power analysis.

Beneath the surface, however, the story changed dramatically. Skin carotenoid scores in the supplement group surged by 48.1 percent from baseline, rising significantly by week six and widening further by week twelve, while the placebo group remained essentially flat. Because dietary carotenoid intake, tracked with a validated questionnaire, was similar in both groups, the increase clearly reflected the bioavailability of the capsules themselves, which the lipophilic compounds carried alongside sunflower oil. This matters because only an estimated five to thirty percent of dietary carotenoids are typically absorbed, and the rapid enrichment of skin tissue validates both the formulation and the delivery system.

Two structural markers also moved in the right direction. Transepidermal water loss, which rises when the skin barrier leaks moisture, fell by 31.3 percent from baseline in the supplement group, a change that was statistically significant compared with placebo and supported by a repeated-measures analysis showing an overall treatment effect. Dermal thickness, measured by ultrasound, increased by 11.9 percent in the active group versus 3.6 percent with placebo, a between-group difference in change that also reached significance. The authors suggest that the reduced water loss may stem from carotenoid protection of lipid membranes in the stratum corneum, while the thickening dermis points toward enhanced collagen deposition in the extracellular matrix, since carotenoids such as beta-carotene, lutein, and lycopene have been shown to protect collagen from oxidative degradation and to support its synthesis.

The safety profile was reassuring. Thirteen adverse events were reported across the study, most of them mild, self-limiting gastrointestinal complaints such as bloating, reflux, and loose stools, with similar rates in both groups. There were no serious adverse events and no withdrawals attributed to the treatment, and the harmless skin yellowing known as carotenoderma, a theoretical concern with high carotenoid intakes, did not appear. The researchers caution that whether the 31.3 percent reduction in water loss translates into perceptible relief from dryness cannot be confirmed, because the trial included no patient-reported outcome measures of skin comfort, and that the structural changes detected on ultrasound had not yet ripened into visible surface improvements within twelve weeks.

What the study ultimately delivers is a biologically grounded, cautiously optimistic case rather than a cosmetic miracle. The authors conclude that CaroRite may support antioxidant status, barrier function, and dermal structure, key parameters for long-term skin health that can precede detectable changes in visible aging, and they call for longer trials, alternative doses, combination formulations, and populations with more advanced photoaging, as well as men and older adults excluded from this study. For consumers tempted by the promise of a wrinkle-free capsule, the message is tempered: twelve weeks of carotenoids made these women’s skin measurably healthier under the hood, but erasing the lines etched by decades of time, gravity, and sunlight remains a far slower and harder project than nourishing the living tissue underneath.

Subject of Research: Effects of oral mixed-carotenoid supplementation on skin health and visible signs of aging in healthy middle-aged women

Article Title: CaroRite™ for improving skin health and the visible signs of aging – a randomised, double-blind, placebo-controlled trial

Article References: Rao, A., Pellow, J., & Briskey, D. (2026). CaroRite™ for improving skin health and the visible signs of aging – a randomised, double-blind, placebo-controlled trial. Frontiers in Aging, 7, Article 1858090. https://doi.org/10.3389/fragi.2026.1858090

Image Credits: AI Generated

DOI: 10.3389/fragi.2026.1858090

Keywords: carotenoids, skin aging, CaroRite, transepidermal water loss, dermal thickness, randomized controlled trial, nutricosmetics, skin barrier, lutein, beta-carotene, lycopene, antioxidants

Foot xerosis, the clinical term for abnormally dry skin, is remarkably common in diabetes. Chronically elevated blood sugar impairs sweating, nerve function and the skin’s barrier machinery, leaving the stratum corneum, the outermost layer of the skin, parched and prone to cracking. Once cracks form, bacteria can enter, and in people with diabetes, whose immune defenses and circulation may already be compromised, a small fissure can spiral into a foot ulcer. Roughly 4 to 10 percent of people with diabetes develop such ulcers, and the lifetime risk may reach 34 percent. Despite this, patients are routinely told to apply foot creams without any firm guidance about which type, because most commercial products have never been evaluated specifically in the diabetic population.

The Swedish team, led by Karin Borgström, set out to close that gap with a review conducted to the exacting standards of Cochrane, the international benchmark for evidence synthesis. The researchers searched five major databases, Medline, Cinahl, Embase, CENTRAL and Scopus, without language or date restrictions, and screened 8,386 records before landing on 11 publications reporting 12 randomized controlled trials involving 603 participants and 949 feet. Only trials in adults with type 1 or type 2 diabetes and foot xerosis, but without existing ulcers, were eligible. The protocol was registered in advance on PROSPERO, and the team assessed risk of bias with the Cochrane RoB 2.0 tool and graded confidence in each result using the GRADE framework, a level of methodological rigor that previous reviews on the topic lacked.

The central comparison pitted functional creams, base formulations with added ingredients intended to enhance their performance, most commonly humectants such as urea and glycerol, against standard base creams lacking those additives. The distinction matters because these ingredient classes work through complementary mechanisms. Moisturizers form hydrophobic, occlusive films that reduce transepidermal water loss, while humectants attract and retain water within the stratum corneum and, intriguingly, keep the proteins and lipids of the skin barrier molecularly mobile even under dry conditions, preserving flexibility and barrier function beyond simple hydration.

The pooled results told a consistent story. After two weeks of treatment, functional creams significantly reduced xerosis severity compared with standard bases, with a standardized mean difference of -0.58, though heterogeneity between trials was high. By four weeks, the benefit persisted at -0.30 with zero heterogeneity, and the certainty of evidence was rated high. Skin hydration, measured by corneometry, also improved significantly with functional creams after both two and four weeks, although the certainty here was low, largely because studies measured hydration at different anatomical sites on the foot. Crucially, when the two trials judged to be at high risk of bias were excluded in sensitivity analyses, the effect remained significant and heterogeneity collapsed to zero, a sign the finding is robust rather than an artifact of flawed studies.

The single most striking result concerned urea. Across six studies, urea-containing creams beat standard base creams after four weeks with a standardized mean difference of -0.36, backed by high-certainty evidence. Even more compelling, two trials directly compared a urea, arginine and carnosine cream with glycerol-based products, one containing 40 percent glycerol and another 15 percent, and the urea formulation won decisively, with a standardized mean difference of -1.09 and high certainty. Urea was the most frequently studied humectant, which the authors caution may reflect research attention rather than proven superiority, but the head-to-head comparisons lend weight to the idea that urea offers something glycerol alone does not.

Not every comparison produced clear answers. A single study testing a plant-based anionic phospholipid emulsion, an emollient rather than a humectant, showed the smallest effect in the analysis, but one trial is too little to draw conclusions. Transepidermal water loss, a proxy for skin barrier integrity, fell significantly after two weeks in one trial but not at four weeks, and the data were too limited to judge. Adverse events across all trials were rare and mild, ranging from a transient burning sensation to one case of interdigital maceration judged probably treatment-related, an encouraging safety signal even if short follow-up periods temper firm safety claims.

The review also spotlighted an elegant trial design that much of this field relies on: the within-person, or split-foot, study, in which one foot receives the active cream and the other the control. Nine of the twelve trials used this approach, and it confers real statistical power by letting each participant serve as their own control, eliminating between-person variability. But it carries subtle risks, including cross-contamination when patients self-apply creams, baseline asymmetry between feet, and the possibility of unblinding when participants can feel or smell differences between products. The authors recommend objective outcome measures, such as corneometry, to guard against these biases, and their sensitivity analyses showed the pooled estimates barely moved when the design question was tested.

Perhaps the most sobering limitation is a structural one: the field lacks a common yardstick. Studies measured xerosis severity with scales ranging from 0-3 to 0-8, forcing the reviewers to use standardized mean differences, which express effects in standard deviation units that clinicians find hard to translate into practice. Urea concentrations varied from 5 to 25 percent, often alongside other ingredients, making it impossible to pin the benefit on urea itself or identify a dose-response relationship. No trial followed participants long enough to answer the question that ultimately matters most, whether better moisturized feet translate into fewer ulcers, amputations or deaths.

Even so, the practical message is clear and actionable today: for people with diabetes battling dry feet, a humectant-containing functional cream, ideally with urea, is a better bet than a plain emollient, and the evidence supporting that choice is now of genuinely high certainty for the four-week xerosis outcome. What comes next, the authors argue, is a new generation of adequately powered randomized trials with standardized formulations, agreed severity scales, prospective protocol registration and, above all, long-term follow-up tracking the outcomes that define diabetic foot disease. Given that the global diabetes population is projected to swell to 783 million by 2045, turning foot cream from folklore into evidence-based prevention could spare an enormous number of people from one of medicine’s most feared complications.

Subject of Research: Moisturizer efficacy for diabetic foot xerosis

Article Title: Moisturizer formulations for diabetic foot xerosis: a systematic review and meta-analysis of randomized controlled trials

Article References: Borgström, K., Björklund, S., Gudmundsson, P., Ericsson, A., & Acosta, S. (2026). Moisturizer formulations for diabetic foot xerosis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Clinical Diabetes and Healthcare, 7, Article 1922860. https://doi.org/10.3389/fcdhc.2026.1922860

Image Credits: AI Generated

DOI: 10.3389/fcdhc.2026.1922860

Keywords: diabetes, diabetic foot, xerosis, moisturizer, urea, humectants, systematic review, meta-analysis, skin barrier, foot ulcers, skincare, randomized controlled trials

Costello syndrome is a member of a family of disorders known as RASopathies, all of which arise from mutations that over-activate the RAS-MAPK signaling pathway, a molecular circuit that governs cell proliferation and differentiation. In Costello syndrome, the culprit is a heterozygous activating variant in the HRAS proto-oncogene on chromosome 11p15.5. The resulting condition affects multiple organ systems: patients display distinctive craniofacial features, curly sparse hair, deep creases on the palms and soles, cardiac abnormalities such as hypertrophic cardiomyopathy and arrhythmias, feeding difficulties and failure to thrive from birth, developmental delay, and an elevated lifetime risk of malignancies including rhabdomyosarcoma, neuroblastoma, and bladder carcinoma.

What has drawn increasing scientific attention, however, is the skin. Eczema has long been noted in Costello syndrome, and a study by Siegel and colleagues found eczematous lesions in nearly a quarter of patients carrying HRAS variants. Recent laboratory work has begun to explain why. In a mouse model of Costello syndrome carrying the activating HRAS c.34G>A, p.(Gly12Ser) variant, Katata and colleagues showed that exposure to house dust mites reliably triggered atopic dermatitis-like lesions. The mechanism traced back to the keratinocytes themselves: hyperactive RAS-ERK signaling in the epidermis impaired the skin barrier and stimulated production of epithelial-derived alarmins, the alarm cytokines interleukin-33 and thymic stromal lymphopoietin, which in turn ignited type 2 inflammation. RAS-ERK activation also stabilizes the transcription factor GATA3 in T cells, steering them toward a type 2 helper fate.

The newly reported patient illustrates this biology in human form with unusual clarity. Born at 37 weeks and 3 days after a pregnancy complicated by polyhydramnios and threatened preterm labor, she weighed 3,980 grams and was large for gestational age. She spent her first weeks in a neonatal intensive care unit with persistent tachypnea requiring supplemental oxygen until day of life 22, and feeding difficulties kept her on tube feeding until day of life 40. During infancy, clinicians noted hepatomegaly, shortened extremities, macroglossia, curly sparse hair, and characteristic facial features, but chromosomal analysis, newborn screening, echocardiography, brain MRI, and hearing tests all failed to yield a diagnosis.

The skin told a more alarming story. At roughly one month of age she developed severe eczematous lesions that met the Hanifin and Rajka diagnostic criteria for atopic dermatitis, yet topical corticosteroids and emollients could not control them; the eczema and pruritus persisted, occasionally bleeding and eroding. By 6 months of age her laboratory values painted a picture of raging type 2 inflammation: total IgE of 138 kU/L, thymus and activation-regulated chemokine, or TARC, of 4,744 pg/mL, and eosinophilia at 9.6 percent with an absolute count of 1,325 cells per microliter. Specific IgE testing revealed striking sensitization to egg white at 57.2 UA/mL and cow’s milk at 34.0 UA/mL, prompting elimination of both foods.

The allergic burden deepened along what immunologists call the atopic march, the sequential emergence of eczema, food allergy, asthma, and allergic rhinitis. Oral food challenges beginning at 3 years and 10 months of age repeatedly provoked immediate reactions as her intake was escalated, and an epinephrine auto-injector was prescribed. At age 10 she used it for full anaphylaxis after accidentally eating chocolate containing cow’s milk. Hen’s egg allergy eventually resolved at 12 years, but cow’s milk allergy persisted into adolescence. Wheezing episodes during respiratory infections from around age 2 or 3 led to suspected asthma and regular leukotriene receptor antagonist therapy, while growth faltered, with height falling to approximately minus 5 standard deviations.

The diagnostic odyssey ended at age 7 years and 10 months, when she joined Japan’s Initiative on Rare and Undiagnosed Diseases and underwent whole-exome sequencing. The analysis identified a heterozygous de novo HRAS variant, NM_005343.4:c.37G>T, p.(Gly13Cys), confirming Costello syndrome. This variant is notable because it produces a milder phenotype than the more intensively studied c.34G>A variant: Gripp and colleagues reported less severe short stature, facial coarsening, and cognitive impairment, along with lower frequencies of multifocal atrial tachycardia, papillomata, and neurosurgical interventions, but distinctive findings such as dolichocilia and loose anagen hair. Consistent with that profile, this patient had no cardiac complications, yet her allergic manifestations were anything but mild, a discrepancy the authors caution makes it risky to extrapolate directly from the mouse model mechanism.

By age 14, with roughly 20 percent of her body surface area affected, an Eczema Area and Severity Index score of 16, and an Investigator’s Global Assessment score of 4 despite appropriate high-potency topical corticosteroids, her team turned to dupilumab. The monoclonal antibody blocks the shared receptor component for interleukin-4 and interleukin-13, the two cytokines at the core of type 2 inflammation, and the authors judged targeted inhibition of that axis a rational approach for a patient with her IgE, TARC, and eosinophil profile, and preferable to broader systemic immunosuppression given the anticipated long-term treatment and the malignancy risk inherent to Costello syndrome. She received a 400 milligram loading dose followed by 200 milligrams every two weeks.

The response was rapid and unequivocal. Within one month her eczematous lesions had almost completely resolved, and the improvement was maintained through six months of follow-up with no serious drug-related adverse events. Equally important was what the change meant for daily life: the patient and her family reported a substantial reduction in the burden of skin care and itching, along with better participation in school activities, a meaningful outcome for a teenager who had spent more than a decade managing bleeding skin.

The authors are careful about what this single case can and cannot prove. Family members had allergic diseases, so ordinary atopic predisposition and environmental factors likely contributed to her severity, and it remains unclear whether HRAS activation directly amplified egg- or milk-specific IgE production. No direct mechanistic evidence was obtained linking her mutation to epithelial-driven inflammation. Still, the genetically confirmed diagnosis, the detailed longitudinal follow-up from infancy, and the swift response to IL-4/IL-13 blockade are consistent with the idea that keratinocyte-driven type 2 inflammation amplified her atopic tendency. Dupilumab experience in Costello syndrome remains limited and long-term efficacy and safety are not established, so the authors urge careful continued surveillance. Even so, the case suggests that refractory eczema in Costello syndrome, too often treated as an intractable consequence of the syndrome itself, may be a treatable inflammatory disease in its own right.

Subject of Research: Dupilumab treatment of refractory atopic dermatitis-like eczema in Costello syndrome

Article Title: Case Report: Successful dupilumab treatment for refractory atopic dermatitis-like eczema in a patient with Costello syndrome

Article References: Nonaka, T., Kido, J., Ogata, M., Miyake, T., Yoshida, T., Fukushima, S., Seyama, R., Uchiyama, Y., Matsumoto, N., & Nakamura, K. (2026). Case Report: Successful dupilumab treatment for refractory atopic dermatitis-like eczema in a patient with Costello syndrome. Journal of Cutaneous Immunology and Allergy, 9, Article 17346. https://doi.org/10.3389/jcia.2026.17346

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.17346

Keywords: Costello syndrome, dupilumab, atopic dermatitis, HRAS, RASopathy, type 2 inflammation, food allergy, interleukin-4, interleukin-13, skin barrier, case report, biologic therapy

Atopic dermatitis is far more than a cosmetic nuisance. It is a chronic, relapsing inflammatory skin disease characterized by eczematous lesions and intense itching, driven by a tangle of genetic predisposition, environmental triggers, skin barrier dysfunction, and immune dysregulation. While it affects roughly 7 to 10 percent of adults worldwide, prevalence in children can reach 25 percent, and Japanese surveys have reported rates as high as 27 percent among preschool children. The consequences ripple through entire households: disrupted sleep, impaired quality of life for children and their guardians, and the daily grind of applying multiple treatments. For most patients, topical therapies remain the mainstay of management, yet the workhorse drugs, topical corticosteroids, carry well-known limitations for long-term use, including the risk of skin atrophy.

Treatment guidelines in Japan emphasize reaching and maintaining a stable state in which signs and symptoms are absent or minimal without interfering with daily activities. Although biologics and other systemic therapies exist for refractory moderate-to-severe disease, the vast majority of children depend on creams and ointments. In recent years, nonsteroidal options such as Janus kinase inhibitors and phosphodiesterase-4 inhibitors have broadened the arsenal, but clinicians continue to call for effective topical agents with new mechanisms. Tapinarof answers that call with an unusual biological strategy: rather than suppressing inflammation broadly, it activates the aryl hydrocarbon receptor, a transcription factor that downregulates inflammatory cytokines implicated in atopic dermatitis while simultaneously upregulating components of the skin barrier.

That dual action is what makes the drug scientifically interesting. By engaging the aryl hydrocarbon receptor, tapinarof appears to improve measurable markers of barrier health, including stratum corneum hydration and transepidermal water loss, according to earlier clinical work in Japanese patients. The compound also activates the nuclear factor erythroid 2 related factor 2 pathway, which ramps up antioxidant enzymes and reduces oxidative stress in the skin. In effect, the drug does not merely quiet inflammation; it appears to help rebuild the defective barrier that lies at the heart of the disease. Tapinarof cream 1 percent is already approved for atopic dermatitis in patients aged 2 and older in the United States and the United Arab Emirates, and for patients 12 and older in Japan, where a phase 2 trial in younger children identified the 0.5 percent strength as the preferred formulation for this age group.

The new phase 3 trial, conducted between August 2023 and March 2025 at 27 sites in Japan, enrolled 162 children and was structured in two parts. The first was an 8-week, double-blind, vehicle-controlled period in which patients were randomized 2:1 to tapinarof cream 0.5 percent or an inactive vehicle cream, with allocation balanced by age category and baseline disease severity. The second was a 52-week open-label extension in which 151 patients who continued into that phase all received active treatment. Families applied a thin layer of cream once daily to all eczema lesions, excluding the hairy scalp, and children were required to have mild to severe disease at baseline, with an Eczema Area and Severity Index score of at least 5 and 5 to 30 percent of body surface area affected. The two groups were well matched, with mean baseline EASI scores of about 10.9 and 10.7 and roughly 60 percent of participants rated as having moderate disease.

The headline result was unambiguous. At week 8, 52.59 percent of children treated with tapinarof achieved a 75 percent or greater improvement in their EASI score, the trial’s primary endpoint, compared with just 12.60 percent of those on vehicle cream, a difference of 40 percentage points with a p value below 0.0001. On the key secondary endpoint, 26.2 percent of tapinarof-treated children reached treatment success on the Investigator’s Global Assessment, meaning their skin was rated clear or almost clear with at least a two-grade improvement, versus only 1.8 percent on vehicle. The mean percent reduction in EASI score was 68.28 percent with tapinarof compared with 23.01 percent with vehicle. Patient-reported measures reinforced the clinical picture: improvements in the Patient-Oriented Eczema Measure appeared from week 2 onward, and itch scores, recorded twice daily in diaries by guardians, fell rapidly after treatment began.

Perhaps the most striking findings emerged over the long haul. Among children who stayed on tapinarof, the EASI-75 response rate climbed from 53.4 percent at week 8 to 75.8 percent at week 32 and 80.2 percent at week 60, while global assessment treatment success rose from 24.3 percent to 48.5 percent and then 56.3 percent over the same span. Children who started on vehicle and switched to the active cream showed a rapid catch-up, reaching EASI-75 rates of 84.8 percent at week 32 and 82.8 percent at week 60. Notably, most patients continued applying the cream even after their lesions cleared, with roughly 80 percent accumulating at least 48 weeks of exposure, and the benefits were maintained without apparent differences between the 2-to-6 and 7-to-11 age groups. Rescue therapy with topical corticosteroids was needed by only about 20 percent of patients during the extension period.

The safety profile proved equally reassuring. Across the entire 60 weeks, no treatment-related serious adverse events were reported, and all treatment-related events were mild or moderate. During the double-blind period, adverse events occurred at similar rates in both groups, driven largely by everyday childhood infections such as nasopharyngitis and influenza. The most common treatment-related events with tapinarof were folliculitis and acne, including application-site folliculitis in 4.5 percent and acne in 3.9 percent of patients over the full trial. The authors attribute these follicular events to increased cornification within hair follicles, a downstream consequence of the drug’s upregulation of barrier proteins such as filaggrin, hornerin, and involucrin, giving them a morphology resembling keratosis pilaris. Only 2.6 percent of patients discontinued due to adverse events in the overall period, and pharmacokinetic sampling showed tapinarof plasma concentrations below the detection limit of 50 picograms per milliliter in at least 80 percent of children at every time point, confirming minimal systemic absorption.

The trial does have limitations worth noting. Most enrolled children had mild or moderate disease, and only four had severe eczema, so the findings may not fully generalize to the most severely affected patients. The comparator was vehicle cream rather than an active standard of care, leaving tapinarof’s superiority over existing topical therapies untested, and children under 2 years of age, in whom the disease is also prevalent, were not included, although a separate 52-week trial in patients aged 3 to 24 months is now underway in Japan. Long-term efficacy analyses also relied on observed cases without imputation and allowed treatment interruptions after clearance. Still, the overall message is clear: a once-daily, steroid-free cream that harnesses the aryl hydrocarbon receptor to both calm inflammation and rebuild the skin barrier delivered substantial, durable, and well-tolerated benefit in young children over more than a year of use. For families exhausted by the cycle of flares, steroids, and sleepless nights, tapinarof may soon offer a genuinely new way forward.

Subject of Research: Efficacy and safety of topical tapinarof cream in Japanese pediatric patients with atopic dermatitis

Article Title: Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period

Article References: Igarashi, A., Tsuji, G., Murata, R., Fukasawa, S., & Yamane, S. (2026). Efficacy and safety of tapinarof cream once daily in Japanese pediatric patients with atopic dermatitis: a 60-week phase 3 trial consisting of an 8-week, double-blind, vehicle-controlled period and a 52-week, open-label extension period. Journal of Cutaneous Immunology and Allergy, 9, Article 17307. https://doi.org/10.3389/jcia.2026.17307

Image Credits: AI Generated

DOI: 10.3389/jcia.2026.17307

Keywords: tapinarof, atopic dermatitis, aryl hydrocarbon receptor, pediatric patients, phase 3 trial, topical treatment, eczema, EASI-75, skin barrier, nonsteroidal therapy, folliculitis, Japan

The study, led by Ajay Pandey and senior author Raj Chovatiya, drew on the National Ambulatory Medical Care Survey, a federally administered dataset that captures representative snapshots of visits to office-based physicians across the country. By pooling survey waves from 2003 through 2015, the researchers assembled a weighted sample of approximately 12.4 billion ambulatory care visits, an enormous denominator that allowed them to examine relatively uncommon diagnoses with meaningful statistical precision. Within that population, roughly 0.10 percent of visits involved seborrheic dermatitis and 0.23 percent involved psoriasis, figures that reflect the share of routine outpatient encounters rather than the prevalence of the diseases in the general population.

The central result was striking in its symmetry. Patients with psoriasis had more than eightfold increased odds of having a comorbid seborrheic dermatitis diagnosis, with an adjusted odds ratio of 8.36 and a 95 percent confidence interval running from 4.28 to 16.32. When the analysis was reversed, patients with seborrheic dermatitis showed nearly identical odds of also having psoriasis, at an adjusted odds ratio of 8.19. Both associations were highly statistically significant, with p values below 0.0001. The bidirectional consistency matters because it argues against a one-way artifact, such as dermatologists simply being more likely to note a second diagnosis once one inflammatory skin disease is already on the chart.

To understand why this overlap exists, it helps to look at the biology the two diseases share. Seborrheic dermatitis is classically associated with the lipophilic yeast Malassezia, which colonizes sebum-rich areas of the skin such as the scalp, eyebrows, nasolabial folds, and chest. The yeast is not simply an infection; rather, its metabolic activity and presence appear to trigger an innate immune response involving inflammasome activation and downstream T helper cell signaling. Psoriasis, by contrast, is driven by a cascade centered on interleukin-23 and interleukin-17, producing the accelerated keratinocyte proliferation and plaques that define the disease. Yet the two pathways converge in important ways, including shared involvement of T helper 17 signaling, antimicrobial peptide dysregulation, and defects in the skin barrier that permit both microbial colonization and inflammatory amplification.

This immunological common ground is what gave rise to the term sebopsoriasis, describing patients whose clinical presentation blends features of both conditions, often in the scalp and facial regions where the diseases are difficult to distinguish. Previous systematic reviews and meta-analyses, including work published by overlapping author groups in 2024, had suggested an elevated co-occurrence of the two diseases in clinical studies. What the new analysis adds is population-level evidence drawn from ordinary outpatient practice rather than from specialized referral centers, where selection bias could inflate apparent associations. The consistency of the eightfold signal across such a broad, nationally representative sample strengthens the case that the comorbidity is genuine rather than an artifact of tertiary care.

Perhaps the most clinically consequential finding, however, concerned what did not differ. The researchers examined healthcare resource utilization metrics, including the time patients spent with their physicians and the number of healthcare visits, and found no significant differences among patients with psoriasis alone, seborrheic dermatitis alone, or both conditions together. On the surface, that might suggest that comorbid disease does not impose a heavier burden on the healthcare system. But the authors caution that these are coarse measures. A single office visit may absorb substantial complexity without registering as longer or more frequent, and the survey data cannot capture prescriptions filled, emergency department use, or the cumulative toll of managing two chronic conditions simultaneously.

Where the groups clearly diverged was in prescribing patterns. Patients carrying both diagnoses were significantly more likely to receive topical antifungal agents, combination topical corticosteroid and vitamin D analog formulations, and topical sulfur preparations. They were also numerically the most likely to be prescribed systemic antibiotics, topical corticosteroids, and topical salicylic acid. That prescription fingerprint tells a story of therapeutic improvisation. Combination corticosteroid and vitamin D analog products are a mainstay of psoriasis treatment, while antifungals target the Malassezia-driven component of seborrheic dermatitis. Patients with both diseases appear to receive a blended regimen that addresses both inflammatory axes at once, even though no formal treatment guidelines exist for the overlap syndrome.

The absence of dedicated guidance is precisely why the authors argue that more research is needed. If sebopsoriasis represents a distinct immunological phenotype rather than simple coincidence, it may respond differently to emerging targeted therapies. Recent dermatology literature has explored phosphodiesterase 4 inhibitor-responsive dermatoses as an emerging concept, and expert consensus panels have weighed the risks of long-term topical corticosteroid therapy against newer advanced topical treatments for inflammatory skin disease. Multi-omics studies published in 2025 have begun identifying shared diagnostic targets between seborrheic dermatitis and scalp psoriasis, hinting that molecular signatures could eventually guide therapy selection for patients whose disease straddles the two diagnoses.

There are also broader implications for how the conditions are studied. A 2026 retrospective cohort study reported bidirectional associations between seborrheic dermatitis and a range of epithelial barrier diseases, and separate JAMA Dermatology work documented elevated rates of epithelial barrier diseases among adults with seborrheic dermatitis. Taken together with the new ambulatory care analysis, a picture emerges of seborrheic dermatitis not as an isolated cosmetic nuisance but as a condition embedded in a wider network of barrier and immune dysfunction. That reframing could influence screening practices, encouraging clinicians who diagnose one inflammatory skin disease to consider whether a second, subtly different process is also at play, particularly in overlapping anatomical territories.

The study is not without limitations, and the authors are careful about what their data can and cannot show. Cross-sectional survey data capture associations at single points in time and cannot establish that one disease causes the other, nor can they distinguish whether the comorbidity reflects shared genetic susceptibility, common environmental triggers such as Malassezia colonization and barrier injury, or diagnostic clustering by physicians. The weighted prevalence figures describe visits rather than people, so they cannot be read directly as population prevalence. Still, with an effect size as large as eightfold in both directions, drawn from billions of weighted encounters, the signal is difficult to dismiss. For the millions of patients living with these chronic, relapsing conditions, the message is that the boundary between dandruff’s inflammatory cousin and psoriasis may be blurrier than the clinic’s diagnostic codes suggest, and that treatment for one may need to account for the other.

Subject of Research: The association between seborrheic dermatitis and psoriasis and its impact on healthcare utilization and prescribing patterns in the United States

Article Title: Association of seborrheic dermatitis and psoriasis and impact on healthcare utilization in the United States

Article References: Pandey, A., Hopkins, T., Maher, S., & Chovatiya, R. (2026). Association of seborrheic dermatitis and psoriasis and impact on healthcare utilization in the United States. Archives of Dermatological Research, 318(1), Article 399. https://doi.org/10.1007/s00403-026-04886-z

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04886-z

Keywords: seborrheic dermatitis, psoriasis, sebopsoriasis, comorbidity, dermatology, healthcare utilization, NAMCS, Malassezia, topical corticosteroids, skin barrier, inflammatory skin disease, prescribing patterns

The study, led by dermatologist Zekiye Kanat and colleagues at Inonu University School of Medicine in Malatya, drew on clinical records spanning nearly six years, from January 2020 to November 2025. The researchers identified 113 patients who had presented to the dermatology outpatient clinic and received a clinical diagnosis of verrucae, the medical term for the rough, raised lesions that human papillomavirus induces when it infects keratinocytes in the epidermis. As a comparison group, they assembled 250 age- and sex-matched healthy individuals. Matching by age and sex was a deliberate methodological choice, since both factors are known to influence wart prevalence, and any imbalance between the groups could have masqueraded as a blood group effect. Ethical approval for the retrospective design was granted by the Inonu University Health Sciences Research Ethics Committee in November 2025.

The numbers tell a straightforward story. In the patient group, the most common blood group was O, accounting for 44.2 percent of cases, while in the control group blood group A predominated at 45.6 percent. On its face, that difference might look intriguing, but statistical testing told a different tale. A chi-square comparison of the ABO distributions between the two groups yielded a p-value of 0.293, well above the conventional threshold of 0.05, meaning the observed variation was entirely compatible with random sampling noise. Rh status told the same story: positive and negative blood types were distributed almost identically between wart patients and controls, with a p-value of 0.534. Even age, the variable most carefully controlled in the design, showed no difference between the groups, with a p-value of 0.387 confirming the success of the matching procedure.

To go beyond simple comparisons, the team built a multiple logistic regression model, a statistical technique that estimates the independent contribution of each variable, blood group, Rh status, sex, and age, to the probability of having warts while holding the others constant. The results were striking in what they failed to find. No variable reached statistical significance. The closest contender was male sex, which carried an odds ratio of 1.573, suggesting that men in this cohort were somewhat more likely to have warts than women, but the p-value of 0.057 fell just short of the significance threshold. More telling still was the model’s explanatory power: a Nagelkerke R-squared of 0.033 means the entire set of variables explained barely three percent of the variation in wart occurrence. In practical terms, blood type and demographics were nearly useless for predicting who develops warts.

The clinical details of the cohort add texture to the statistical findings. Wart lesions were most commonly located on the hands, which accounted for 45.1 percent of cases, followed by the feet at 39.8 percent. That distribution is consistent with what dermatologists see in everyday practice and with the biology of transmission. Cutaneous warts spread through direct contact and through autoinoculation, and the hands and feet are the body surfaces most exposed to microtrauma, small breaks in the skin barrier that give papillomavirus particles access to the basal keratinocytes they must infect to establish a lesion. Swimming pools, communal showers, and occupational handling are classic routes of exposure, and the anatomic distribution of lesions in this study mirrors those routes rather than any immunogenetic pattern.

The null result matters because the hypothesis it tested was biologically plausible. ABO blood group antigens are carbohydrate structures synthesized by specific glycosyltransferase enzymes, and they are expressed not only on red blood cells but also on the surface of many epithelial and endothelial cells. Viruses, in turn, often rely on specific surface glycans as attachment factors or receptors. Norovirus strains, for example, bind histo-blood group antigens in the gut, which is why secretor status and blood group shape susceptibility to that virus. Helicobacter pylori exploits Lewis antigens, and some influenza strains show blood group-dependent binding patterns. A 2023 systematic review and meta-analysis published in BMC Infectious Diseases found associations between ABO type and the risk of several infections, and studies during the COVID-19 pandemic reported that group O individuals appeared at somewhat lower risk of SARS-CoV-2 infection, possibly because circulating anti-A and anti-B antibodies or differences in glycan expression modulate viral entry and immune recognition.

There is even a dermatological thread to this literature. Earlier studies have explored links between ABO blood groups and skin conditions ranging from lichen planus and pemphigoid to psoriasis vulgaris and acne severity, with mixed and often inconsistent results. One Turkish study published in 2019 examined blood groups and anogenital wart development, and researchers have also investigated blood type associations with nonmelanoma skin cancers. Recent work has added mechanistic depth: a 2024 study in Biology Research showed that H antigen expression, the glycan precursor shared by group O individuals, modulates the integrity and differentiation of epidermal keratinocytes, the very cells that papillomavirus infects. That finding made the wart hypothesis genuinely worth testing, since altered keratinocyte differentiation could theoretically change the permissiveness of the skin to viral replication.

Why, then, did no association emerge? The authors point toward the established drivers of wart pathogenesis, which operate on a different biological level. Immunosuppression is the single most powerful risk factor for cutaneous warts; transplant recipients on calcineurin inhibitors and people with advanced HIV infection can develop extensive, recalcitrant lesions, and immunodeficiency is associated with a dramatically elevated burden of HPV-related disease. Local trauma determines where lesions appear and whether inoculation succeeds. And above all, HPV genotype matters: more than 200 papillomavirus types have been described, and the alpha, beta, gamma, and mu genera infect different body sites with different clinical consequences. The interplay between a specific viral type and the local immune microenvironment of the skin likely dwarfs any subtle effect of red cell surface glycans. A retrospective design also has limits; blood group was extracted from existing records, wart diagnosis was clinical rather than HPV-genotype-confirmed, and a cohort of 113 cases may simply lack the statistical power to detect a small true effect, if one exists.

For the public, the takeaway is refreshingly simple. Knowing your blood type will not tell you whether you are likely to catch warts, and no blood group confers protection against them. Prevention still rests on the familiar pillars: avoiding direct contact with lesions, not picking or shaving over existing warts, keeping skin intact and moisturized in high-exposure settings, and seeking treatment early, since options from salicylic acid and cryotherapy to newer immunotherapies work best before lesions become large and established. For researchers, the study adds a well-designed negative result to a literature often criticized for chasing weak associations across dozens of diseases. Negative findings like this one help discipline the field, redirecting attention toward the factors that demonstrably drive infection, the virus itself, the state of the host immune system, and the microenvironment of the skin barrier. In the ongoing effort to map human genetic susceptibility to viral disease, the ABO and Rh systems, at least for cutaneous warts, can now be crossed off the list.

Subject of Research: The association between ABO/Rh blood groups and cutaneous viral warts caused by human papillomavirus

Article Title: The relationship between cutaneous viral warts and ABO/RH blood groups: a retrospective case-control study

Article References: Kanat, Z., Türkmen, D., Altunişik, N., Şener, S., Kayhan Teti̇k, B., & Güner, M. E. (2026). The relationship between cutaneous viral warts and ABO/RH blood groups: a retrospective case-control study. Archives of Dermatological Research, 318(1), Article 397. https://doi.org/10.1007/s00403-026-04858-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04858-3

Keywords: viral warts, human papillomavirus, ABO blood groups, Rh factor, dermatology, case-control study, verrucae, host susceptibility, immunosuppression, skin barrier, logistic regression, blood group antigens

Transepidermal water loss, or TEWL, is the standard scientific measure of how well the skin’s outermost layer, the stratum corneum, holds water inside the body. In adults, this barrier is so effective that water loss through the skin is minimal. In babies born at the edge of viability, however, the epidermis is often still a work in progress. The keratinocytes that should form a tightly packed, lipid-rich bricks-and-mortar structure have not yet completed their maturation, and the result is a surface that behaves more like a permeable membrane than a waterproof shield. Earlier landmark studies in infants born at 24 and 25 weeks of gestation documented astonishingly high evaporative losses in the first days of life, enough to drive dangerous shifts in fluid balance, temperature, and blood chemistry.

Chorioamnionitis has long been suspected of adding insult to this injury. The condition is common in preterm birth, and decades of research have linked the fetal inflammatory response it triggers to a catalog of neonatal problems, including lung injury, impaired growth, and neurodevelopmental difficulties. Some pathological studies have even described dermatitis as a component of fetal inflammatory response syndrome, with Toll-like receptor activation detectable in the epidermal keratinocytes of affected infants. What remained unclear was whether this intrauterine inflammation leaves a measurable functional imprint on the newborn skin barrier—something that could be quantified at the bedside rather than only under a microscope.

To find out, the Dublin team enrolled thirty-seven infants born at or below 27 weeks and 6 days of gestation and measured their TEWL on days one, three, and fourteen of life. The measurements were taken with a closed-chamber device inside humidified incubators, using a standardized protocol designed to minimize the confounding effects of ambient humidity and handling. Each infant’s placenta was examined according to the Amsterdam consensus definitions of placental lesions, allowing the researchers to classify babies according to both the presence and the severity of histological inflammation. Thirteen of the thirty-seven infants had histological chorioamnionitis.

On the surface, the headline result seemed straightforward: babies exposed to chorioamnionitis lost more water through their skin on the first day of life than unexposed babies. But when the researchers adjusted statistically for gestational age, that overall difference lost its significance, with a p-value of 0.152. The explanation lay in a more subtle pattern. A significant interaction between gestational age and chorioamnionitis status—p equal to 0.017—was confined to the most immature infants in the cohort, those at or below approximately 25 weeks of gestation. In other words, inflammation in the womb did not uniformly drive up water loss across all preterm babies; it did so specifically where the skin was least developed to begin with.

This gestation-dependent effect is the study’s most intriguing finding, and it carries a clear biological logic. The stratum corneum begins to function as a barrier at roughly the beginning of the third trimester, and its competence improves rapidly between 24 and 34 weeks. A baby born at 25 weeks therefore has a skin barrier that is barely established, with a thin, poorly lipidized horny layer and an immature acid mantle. Adding a fetal inflammatory response—complete with cytokines such as tumor necrosis factor-alpha circulating in fetal tissues—may push that already fragile system past a functional threshold. In slightly older preterm infants, whose barriers have more developmental reserve, the same inflammatory exposure may be absorbed without a measurable penalty in evaporative water loss.

The study also connected higher TEWL to postnatal physiological instability, suggesting that the babies with the leakiest skin were also those struggling most with early adaptation to life outside the womb. This raises the possibility of a feedback loop: a failing barrier allows heat and water to escape, destabilizing temperature and fluid balance, while systemic illness may in turn impair the skin’s capacity to mature. The authors frame their results as hypothesis-generating, proposing that fetal inflammation and early physiological instability may both contribute, alongside simple immaturity, to impaired barrier adaptation in the tiniest newborns. Notably, adjusted TEWL declined between days one and fourteen in the cohort, with the largest difference between exposed and unexposed infants seen on the very first day—consistent with the natural, rapid maturation of the epidermis after birth.

Why does a measurement of water evaporation matter so much clinically? Because fluid management in extremely preterm infants is a delicate balancing act performed with tiny margins. Excessive insensible water loss can cause dehydration, hypernatremia, and the need for increased fluid supplementation, while overcorrection risks fluid overload and its own complications. A very immature infant with a compromised barrier may also be more susceptible to skin injury from adhesives and electrodes, and the skin is increasingly recognized as an immune organ in its own right, with the epidermis serving as a first line of innate defense. If chorioamnionitis-exposed infants at the lowest gestations are uniquely vulnerable to fluid imbalance and skin damage, as the Rotunda team suggests, then caregivers may eventually need to tailor humidity settings, fluid calculations, and skin care protocols specifically for this subgroup.

The authors are careful about the limits of their work. With thirty-seven infants, this is an exploratory, single-centre cohort, and the gestation-adjusted analysis did not retain a significant overall association between chorioamnionitis and TEWL. Illness severity, placental inflammation grading, and postnatal age were all examined as potential modifiers, and the picture that emerges is complex rather than categorical. Nevertheless, the strength of the interaction at the earliest gestations, the standardized closed-chamber methodology, and the use of accepted placental pathology criteria give the findings a credibility that larger follow-up studies can now test. The device used in the study was funded by the hospital’s charitable organization, The Rotunda Foundation, and the authors report no competing interests.

For the broader field of neonatology, the study adds a new organ—the skin—to the list of systems potentially shaped by the intrauterine inflammatory environment. It also reinforces a growing theme in developmental biology: that outcomes after preterm birth are rarely determined by a single variable. Gestational age, placental pathology, and the turbulence of the first postnatal days appear to interlock, and the infants who fare worst are often those exposed to several of these stresses at once. For the smallest and earliest babies, the new data hint that the skin they bring into the world may already carry the memory of the inflammation they experienced before birth—a memory written in the rate at which their bodies lose water to the air.

Subject of Research: The effect of chorioamnionitis exposure on transepidermal water loss and skin barrier maturation in extremely preterm infants

Article Title: A gestation-dependent association between chorioamnionitis and early transepidermal water loss in extremely preterm infants

Article References: McGrath, C. P., & Boyle, M. A. (2026). A gestation-dependent association between chorioamnionitis and early transepidermal water loss in extremely preterm infants. Pediatric Research. https://doi.org/10.1038/s41390-026-05443-0

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05443-0

Keywords: chorioamnionitis, transepidermal water loss, extremely preterm infants, skin barrier, gestational age, placental histopathology, fetal inflammatory response, neonatology, stratum corneum, fluid balance, Pediatric Research, prematurity

Atopic dermatitis affects a substantial share of children, often appearing in the first years of life with intensely itchy, inflamed patches on the face, flexures of the arms and legs, and trunk. Its roots lie in a combination of barrier defects in the skin, genetic susceptibility, and dysregulated immune responses dominated by type 2 inflammatory pathways. Obesity, meanwhile, is no longer viewed as a passive state of energy surplus. Adipose tissue actively secretes hormones, cytokines, and signaling lipids that reshape systemic inflammation. The review’s central premise is that these two biological narratives—barrier failure and immune misfiring on one side, metabolically driven low-grade inflammation on the other—may converge in the same child, with measurable consequences for disease risk and severity.

The research team undertook a systematic synthesis of studies that had previously investigated the relationship between body mass index, overweight, obesity, and atopic dermatitis in pediatric populations. Among the key works the reviewers examined were a 2024 national cross-sectional analysis from Korea published in PLoS ONE, which assessed the association between body mass index and atopic dermatitis among adolescents; case-control studies from 2011 and 2023 that compared obesity rates in children with and without the skin condition; a 2015 JAMA Dermatology investigation linking central obesity with high blood pressure in pediatric atopic dermatitis patients; and a 2022 JAMA Dermatology cohort analysis of atopic dermatitis and growth parameters including height, weight, and body mass index in children. By drawing these threads together, the review offers a consolidated view of a literature that has often produced seemingly inconsistent results.

That inconsistency is itself scientifically revealing. Some studies report that children with obesity carry higher odds of developing atopic dermatitis or experience more severe disease, while others find no meaningful relationship—or even signals pointing the opposite way. One frequently cited example in the literature is a Finnish follow-up study of children after infantile bronchiolitis, which found that overweight did not increase asthma risk and might even be associated with lower allergy risk at school age. Such discordance underscores a central challenge: the direction and strength of any obesity–eczema link may depend on how obesity is measured, whether total body mass or central adiposity is the exposure of interest, how atopic dermatitis is defined, and whether the outcome is diagnosis, severity, or persistence of disease.

Measurement issues loom large in this field. Body mass index, the most widely used metric, is a crude proxy that cannot distinguish lean mass from fat mass or capture the distribution of adipose tissue. Yet fat distribution may matter biologically, because visceral or central obesity generates a more pro-inflammatory milieu than subcutaneous fat. The 2015 JAMA Dermatology study highlighted in the review focused specifically on central obesity and found it associated with elevated blood pressure among children with atopic dermatitis, hinting that the metabolic complications of adiposity and the inflammatory burden of eczema may compound one another. Meanwhile, a longitudinal birth cohort analysis of fetal growth, obesity, and atopic disorders in adolescence suggests that early-life growth trajectories could program later allergic risk, adding a developmental dimension that cross-sectional snapshots cannot capture.

Beneath the epidemiology lies a set of plausible mechanistic pathways. Adipocytes release pro-inflammatory adipokines such as leptin, which can amplify T-cell activity, and reduced levels of anti-inflammatory adiponectin, potentially tipping immune balance toward the type 2 skew characteristic of atopic disease. Obesity is also associated with chronic oxidative stress and altered gut microbiome composition, both of which have been implicated in eczema pathogenesis. Mechanical factors may contribute as well: skin folds in children with obesity create warm, moist microenvironments prone to friction and microbial overgrowth, including colonization by Staphylococcus aureus, a well-known trigger of atopic dermatitis flares. Conversely, the relationship could run in reverse, with itchy, sleep-disrupting eczema limiting physical activity and promoting weight gain—a bidirectional dynamic that most observational studies are poorly equipped to disentangle.

The timing question—does obesity precede eczema, follow it, or simply co-develop—remains the critical unresolved issue, and it is precisely where systematic reviews earn their keep. The McMaster team’s synthesis of case-control designs, which enroll children with and without disease and look backward at exposures, alongside cross-sectional surveys that capture a single moment in time, and longitudinal cohorts that track growth and disease over years, provides a map of where the evidence is strongest and where it frays. Their review, published as a research letter, reflects a deliberate effort to distill a sprawling and sometimes contradictory body of work into a form that clinicians and researchers can act upon, rather than adding another single-population data point to an already crowded field.

For pediatricians and dermatologists, the stakes are practical. If excess adiposity genuinely worsens atopic dermatitis risk or severity, then weight management could become an explicit adjunct to eczema care, complementing emollients, topical anti-inflammatory agents, and the newer systemic therapies that have transformed treatment for moderate-to-severe disease. Conversely, if eczema drives inactivity and weight gain, early aggressive control of itch and inflammation might protect against obesity downstream. Either scenario would justify closer monitoring of growth parameters and metabolic health in children with atopic dermatitis, a population in whom the JAMA Dermatology hypertension findings suggest cardiovascular risk factors may already be converging.

The review also exposes the limitations of the current evidence base. Heterogeneous definitions of pediatric obesity, reliance on parent-reported eczema diagnoses in some surveys, confounding by diet, socioeconomic status, and shared environmental triggers, and the scarcity of interventional data all temper the certainty of any conclusion. The authors note that no datasets were generated or analyzed anew in their study, positioning the work squarely as an interpretive synthesis rather than a primary analysis. Future progress, they and others in the field suggest, will depend on large prospective cohorts with objective adiposity measures, standardized eczema phenotyping, and mediation analyses that can test whether weight change causally shifts disease trajectories.

What emerges from this systematic review is neither a simple alarm nor a dismissal, but a call for precision. Childhood obesity and atopic dermatitis are each formidable public health burdens on their own; the possibility that they amplify one another through shared inflammatory, metabolic, and behavioral pathways makes understanding their intersection a priority. As prevalence curves for both conditions continue to rise, studies like this one from the McMaster group provide the evidentiary scaffolding on which the next generation of longitudinal and mechanistic research—and eventually, targeted prevention strategies—can be built.

Subject of Research: The association between childhood obesity and atopic dermatitis in children

Article Title: The association between childhood obesity and atopic dermatitis: a systematic review

Article References: Sehjal, M., Branyiczky, M. K., Akomolafe, E., & Abu-Hilal, M. (2026). The association between childhood obesity and atopic dermatitis: a systematic review. Archives of Dermatological Research, 318(1), Article 427. https://doi.org/10.1007/s00403-026-04874-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04874-3

Keywords: childhood obesity, atopic dermatitis, eczema, systematic review, pediatrics, inflammation, body mass index, adipokines, skin barrier, immune dysregulation, metabolic health, dermatology

The study, led by Gunther Grinde and Megan Lorenz as co-first authors with senior authorship shared by Kaeli Samson and Erin X. Wei, was conducted as a single-center analysis at the University of Nebraska Medical Center in Omaha. The researchers reviewed records of patients with hidradenitis suppurativa seen at their institution and linked the clinical picture to environmental exposure data drawn from existing, publicly available sources. That pairing of a real-world patient population with objective environmental measurements is what gives the work its interest. Most of what dermatologists know about triggers of the disease comes from patient self-report, small surveys or mechanistic speculation, rather than from systematic comparisons of disease patterns against measured conditions such as temperature, humidity or air quality.

The rationale for looking outward, rather than only inward at the skin itself, rests on a growing body of literature connecting environmental stressors to inflammatory skin disease. A 2025 meta-analysis in JAMA Dermatology synthesized evidence that climate conditions, weather changes and air pollutants are associated with flares of atopic dermatitis, another chronic inflammatory disorder of the skin. Separate reviews have catalogued the mechanisms by which particulate air pollution and climate change damage the skin barrier, alter the microbiome and drive oxidative stress and inflammatory signaling. If pollution and weather can measurably worsen one chronic inflammatory skin disease, the Nebraska team reasoned, it is plausible that they influence hidradenitis suppurativa as well, a disease whose flares many patients anecdotally link to heat, sweating and friction.

The biology behind that suspicion is worth unpacking. Hidradenitis suppurativa is now understood as a disease of the hair follicle, in which follicular occlusion, immune dysregulation and dysbiosis of the skin microbiome combine to produce deep, painful inflammation. Sweat and moisture are central to this cascade. Occluded, damp skin favors bacterial overgrowth and maceration, and apocrine gland-rich regions are precisely where sweat accumulates. Heat and humidity increase sweating; friction from clothing and skin-on-skin contact compounds follicular trauma. Airborne pollutants, meanwhile, can adhere to sweat and sebum on the skin surface, generating reactive oxygen species and disrupting the barrier. In theory, then, a hot, humid, polluted environment should be close to a worst-case scenario for someone predisposed to the disease, and cooler, drier conditions should be more forgiving.

Nebraska offers an interesting natural laboratory for testing such ideas. The state sits in the continental interior, with hot summers, cold winters, wide seasonal swings in humidity and a largely rural and agricultural landscape punctuated by urban centers. Patients seen at a single academic center there will have experienced a broad range of weather and, potentially, differing exposures to agricultural dust, pollen and urban pollution. By anchoring the analysis to one institution, the researchers could reduce some of the confounding that plagues multi-site studies, where differences in diagnostic practice, coding and patient demographics between centers can swamp the environmental signal they are trying to detect. The tradeoff, which the authors acknowledge implicitly by framing the work as a research letter rather than a definitive study, is that a single center’s patient mix may not generalize to other regions or populations.

The methodological architecture of the study reflects this tension between rigor and feasibility. The protocol was reviewed and approved by the University of Nebraska Medical Center Institutional Review Board, with patient consent waived, and the study was conducted in accordance with the Declaration of Helsinki. Patient-level data were not made publicly available because of institutional restrictions and privacy considerations, while the environmental data were obtained from publicly available sources. The statistical analysis was performed by the biostatistics team, and the work was supported in part by the institutional READi biomedical informatics core, which is funded through the National Institutes of Health, the Patient-Centered Outcomes Research Institute and the Nebraska Research Initiative. In other words, this is a carefully governed, modestly resourced study designed to generate hypotheses rather than to settle them.

Why does this kind of hypothesis-generating work matter for patients? Hidradenitis suppurativa is notoriously difficult to manage. Available treatments, from antibiotics and hormonal therapies to biologic drugs that block tumor necrosis factor, help many patients but rarely produce complete, durable remission, and surgical options are reserved for advanced disease. If modifiable environmental factors, such as exposure to extreme heat, high humidity or poor air quality, measurably influence disease activity, they would represent levers that patients and clinicians could actually pull. Counseling a patient to manage sweating, choose breathable clothing or use air filtration during pollution episodes is far cheaper and safer than escalating immunosuppressive therapy, and it aligns with the broader movement in dermatology toward lifestyle and environmental counseling as adjuncts to pharmacologic treatment.

The study also arrives at a moment when the intersection of climate and skin health is moving rapidly up the research agenda. Recent reviews have argued that rising temperatures, shifting humidity patterns, increased ultraviolet exposure and worsening air quality constitute a slow-moving public health problem for the skin, with chronic inflammatory conditions likely to bear a disproportionate share of the burden. For hidradenitis suppurativa specifically, a disease already linked to daily lifestyle factors such as smoking, diet, obesity and sweating, climate change could plausibly shift the geography of flares, lengthening the hot, humid seasons during which patients suffer most. Studies that establish baseline associations between the disease and measured environmental variables are the necessary first step toward projecting those future impacts and designing adaptation strategies for vulnerable populations.

It is equally important to read the findings with appropriate caution. Single-center analyses are vulnerable to selection bias: the patients who reach an academic dermatology clinic in Omaha are not a random sample of everyone with the disease, and referral patterns, insurance status and distance to care all shape who appears in the dataset. Environmental exposure assigned by residence or by the location of the treating center is a crude proxy for what any individual patient actually experiences, since people spend most of their time indoors, travel between climates and differ in occupation, activity level and air-conditioning access. Confounding by socioeconomic factors, which are themselves strongly tied to both disease severity and environmental exposure, is a persistent threat in this literature. The authors declare no conflicts of interest and are transparent about the scope of their data, but the honest conclusion is that environmental associations of hidradenitis suppurativa remain, at this stage, a promising frontier rather than an established clinical fact.

What the Nebraska study ultimately contributes is momentum and a template. By demonstrating that it is feasible to link a well-characterized single-center cohort of hidradenitis suppurativa patients to publicly available environmental data, and by doing so under formal ethical oversight with professional biostatistical support, the team has laid groundwork that larger, multi-center and longitudinal studies can build upon. The logical next steps are clear: follow patients prospectively across seasons, measure exposures at the individual level, and test whether environmental variables predict flares independently of the established risk factors of smoking and obesity. If those studies confirm what this analysis hints at, the management of one of dermatology’s most burdensome diseases may gain a new dimension, one that treats the patient’s environment, not just their skin, as a legitimate target of care.

Subject of Research: Environmental factors associated with hidradenitis suppurativa

Article Title: Environmental associations of hidradenitis suppurativa: a single center analysis

Article References: Grinde, G., Lorenz, M., Kumar, E. A., McGrath, J., Sharma, D., Zhan, Y., Samson, K., & Wei, E. X. (2026). Environmental associations of hidradenitis suppurativa: a single center analysis. Archives of Dermatological Research, 318(1), Article 424. https://doi.org/10.1007/s00403-026-04882-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04882-3

Keywords: hidradenitis suppurativa, dermatology, environmental health, air pollution, climate, heat stress, humidity, skin barrier, chronic inflammation, single-center study, University of Nebraska Medical Center, Archives of Dermatological Research